Enrolling By Invitation PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT06764329
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia: a Randomized, Double-Blind, Placebo Control Trial
Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Conditions
Androgenetic Alopecia Androgenetic Alopecia (AGA)
Interventions
0.9 % saline Mesenchymal Stem Cells
Updated 1 time since 2025 Last updated: Jan 1, 2025 Started: Dec 25, 2024 Primary completion: Jun 30, 2025 Completion: Aug 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Androgenetic Alopecia and Androgenetic Alopecia (AGA), this trial is ongoing. The trial is conducted by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan and has accumulated 1 data snapshot since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Enrolling By Invitation — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Pak Emirates Military Hospital
Data source: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
For direct contact, visit the study record on ClinicalTrials.gov .